Table 2.
Treatment outcomes.
| Characteristics | n = 34 |
|---|---|
| Total IP courses | 165 times |
| Induction IP | 34 (100%) |
| One course of induction IP | 22 (65%) |
| Two courses of induction IP | 6 (18%) |
| Three courses of induction IP | 4 (12%) |
| Four courses of induction IP | 2 (6%) |
| Concomitant therapy | 32 (94%) |
| Completion of concomitant therapy | 25 (74%) |
| Uncompleted concomitant therapy | 9 (26%) |
| Owing to LPD | 3 (9%) |
| Owing to SPD | 3 (9%) |
| Owing to LPD and SPD | 1 (3%) |
| Owing to AEs | 2 (6%) |
| Continued TKI therapy during this study | 11 (32%) |
| Systemic chemotherapy during this study | 1 (3%) |
| Subsequent targeted therapy after this studya | 15 (44%) |
| Subsequent systemic chemotherapy after this study | 6 (18%) |
| Salvage intrathecal chemotherapy | 3 (9%) |
AE, adverse event; IP, intrathecal pemetrexed; LPD, leptomeningeal metastases progressive disease; SPD, systemic progressive disease; TKI, tyrosine kinase inhibitor.
a
Includes EGFR-TKI therapy (n = 14) and bevacizumab (n = 1).